CDXS vs. NVAX, MYGN, INVA, OPK, IRWD, EBS, XOMA, RIGL, VNDA, and VSTM
Should you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Novavax (NVAX), Myriad Genetics (MYGN), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Emergent BioSolutions (EBS), XOMA (XOMA), Rigel Pharmaceuticals (RIGL), Vanda Pharmaceuticals (VNDA), and Verastem (VSTM). These companies are all part of the "biotechnology" industry.
Codexis vs.
Codexis (NASDAQ:CDXS) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking.
Novavax received 499 more outperform votes than Codexis when rated by MarketBeat users. Likewise, 74.11% of users gave Novavax an outperform vote while only 61.47% of users gave Codexis an outperform vote.
In the previous week, Codexis had 3 more articles in the media than Novavax. MarketBeat recorded 7 mentions for Codexis and 4 mentions for Novavax. Codexis' average media sentiment score of 0.74 beat Novavax's score of 0.34 indicating that Codexis is being referred to more favorably in the media.
Codexis presently has a consensus price target of $8.33, suggesting a potential upside of 66.67%. Novavax has a consensus price target of $17.83, suggesting a potential upside of 112.30%. Given Novavax's higher possible upside, analysts clearly believe Novavax is more favorable than Codexis.
Novavax has a net margin of -32.18% compared to Codexis' net margin of -96.35%. Novavax's return on equity of 0.00% beat Codexis' return on equity.
Codexis has higher earnings, but lower revenue than Novavax. Codexis is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
78.5% of Codexis shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 2.1% of Codexis shares are held by insiders. Comparatively, 1.0% of Novavax shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Codexis has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500. Comparatively, Novavax has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.
Summary
Codexis beats Novavax on 9 of the 17 factors compared between the two stocks.
Get Codexis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:CDXS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free CDXS Stock Alerts